{"id":30815,"date":"2025-03-28T12:29:13","date_gmt":"2025-03-28T04:29:13","guid":{"rendered":"https:\/\/flcube.com\/?p=30815"},"modified":"2025-03-28T12:29:15","modified_gmt":"2025-03-28T04:29:15","slug":"microport-cardioflow-medtech-reports-7-5-revenue-growth-in-2024-driven-by-global-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30815","title":{"rendered":"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion"},"content":{"rendered":"\n

China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160<\/a>) announced its 2024 financial report, recording RMB362 million (USD50 million) in revenue, a 7.5% year-on-year (YOY) increase. This growth was driven by the ongoing global commercialization of its flagship products, VitaFlow Liberty and Alwide Plus. The period also saw the official launch of its AnchorMan left atrial appendage occluder system and guidance system in China, adding new revenue streams.<\/p>\n\n\n\n

Product Launches and Revenue Drivers<\/strong>
The AnchorMan systems’ launch in China contributed to the revenue growth, alongside continued demand for VitaFlow Liberty and Alwide Plus. These products have been pivotal in expanding CardioFlow Medtech’s market presence both domestically and internationally.<\/p>\n\n\n\n

TAVI Products’ Global Expansion<\/strong>
Transcatheter aortic valve implantation (TAVI) products made significant inroads globally, accessing over 80 new hospitals in China, bringing the domestic total to 630. The third-generation TAVI product, VitaFlow Liberty, achieved a milestone by becoming the first Chinese intelligent-manufacturing TAVI system with a CE mark in April 2024. By the end of the reporting period, CardioFlow Medtech\u2019s TAVI products had entered nearly 100 hospitals across Argentina, Colombia, Thailand, Russia, Italy, Spain, Chile, Switzerland, and other countries.<\/p>\n\n\n\n

Strategic Acquisition<\/strong>
During the period, CardioFlow Medtech acquired 51% stakes in Shanghai Zuoxin Medical Technology Co., Ltd, marking its entry into the high-growth niche market of stroke prevention in non-valvular atrial fibrillation patients within the structural heart disease sector.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362…<\/p>\n","protected":false},"author":1,"featured_media":30816,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,1133,812,3938],"class_list":["post-30815","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-2160","tag-microport-cardioflow-medtech","tag-zuoxin-medical-technology"],"yoast_head":"\nMicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362 million (USD50 million) in revenue, a 7.5% year-on-year (YOY) increase. This growth was driven by the ongoing global commercialization of its flagship products, VitaFlow Liberty and Alwide Plus. The period also saw the official launch of its AnchorMan left atrial appendage occluder system and guidance system in China, adding new revenue streams.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30815\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion\" \/>\n<meta property=\"og:description\" content=\"China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362 million (USD50 million) in revenue, a 7.5% year-on-year (YOY) increase. This growth was driven by the ongoing global commercialization of its flagship products, VitaFlow Liberty and Alwide Plus. The period also saw the official launch of its AnchorMan left atrial appendage occluder system and guidance system in China, adding new revenue streams.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30815\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-28T04:29:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-28T04:29:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2803-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"459\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30815#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30815\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion\",\"datePublished\":\"2025-03-28T04:29:13+00:00\",\"dateModified\":\"2025-03-28T04:29:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30815\"},\"wordCount\":234,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30815#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2803-png.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 2160\",\"MicroPort CardioFlow Medtech\",\"Zuoxin Medical Technology\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30815#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30815\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30815\",\"name\":\"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30815#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30815#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2803-png.webp\",\"datePublished\":\"2025-03-28T04:29:13+00:00\",\"dateModified\":\"2025-03-28T04:29:15+00:00\",\"description\":\"China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362 million (USD50 million) in revenue, a 7.5% year-on-year (YOY) increase. This growth was driven by the ongoing global commercialization of its flagship products, VitaFlow Liberty and Alwide Plus. The period also saw the official launch of its AnchorMan left atrial appendage occluder system and guidance system in China, adding new revenue streams.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30815#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30815\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30815#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2803-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2803-png.webp\",\"width\":1080,\"height\":459,\"caption\":\"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30815#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion - Insight, China's Pharmaceutical Industry","description":"China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362 million (USD50 million) in revenue, a 7.5% year-on-year (YOY) increase. This growth was driven by the ongoing global commercialization of its flagship products, VitaFlow Liberty and Alwide Plus. The period also saw the official launch of its AnchorMan left atrial appendage occluder system and guidance system in China, adding new revenue streams.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30815","og_locale":"en_US","og_type":"article","og_title":"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion","og_description":"China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362 million (USD50 million) in revenue, a 7.5% year-on-year (YOY) increase. This growth was driven by the ongoing global commercialization of its flagship products, VitaFlow Liberty and Alwide Plus. The period also saw the official launch of its AnchorMan left atrial appendage occluder system and guidance system in China, adding new revenue streams.","og_url":"https:\/\/flcube.com\/?p=30815","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-28T04:29:13+00:00","article_modified_time":"2025-03-28T04:29:15+00:00","og_image":[{"width":1080,"height":459,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2803-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30815#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30815"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion","datePublished":"2025-03-28T04:29:13+00:00","dateModified":"2025-03-28T04:29:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30815"},"wordCount":234,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30815#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2803-png.webp","keywords":["Finanical Reports","HKG: 2160","MicroPort CardioFlow Medtech","Zuoxin Medical Technology"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30815#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30815","url":"https:\/\/flcube.com\/?p=30815","name":"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30815#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30815#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2803-png.webp","datePublished":"2025-03-28T04:29:13+00:00","dateModified":"2025-03-28T04:29:15+00:00","description":"China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362 million (USD50 million) in revenue, a 7.5% year-on-year (YOY) increase. This growth was driven by the ongoing global commercialization of its flagship products, VitaFlow Liberty and Alwide Plus. The period also saw the official launch of its AnchorMan left atrial appendage occluder system and guidance system in China, adding new revenue streams.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30815#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30815"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30815#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2803-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2803-png.webp","width":1080,"height":459,"caption":"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30815#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2803-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30815"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30815\/revisions"}],"predecessor-version":[{"id":30817,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30815\/revisions\/30817"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30816"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}